The global malaria vaccine market is witnessing considerable growth driven by the development of new vaccines. Malaria remains one of the most widespread infectious diseases globally, claiming over 420,000 lives annually. Malaria vaccines help prevent malaria infection by teaching the immune system to recognize and attack the malaria parasite. Several vaccines are currently in clinical trials with the aim of achieving over 75% efficacy required for WHO recommendation and widespread use.
The Global Malaria Vaccines Market is estimated to be valued at USD 620.0 Mn in 2025 and is expected to exhibit a CAGR of 12.7% over the forecast period 2025 to 2032.
Malaria transmission occurs in over 100 countries, primarily in Africa, Asia, and Latin America. The development of an effective malaria vaccine could help control the disease and reduce its substantial health and economic burden.
Key Takeaways
Key players operating in the Malaria Vaccines market are GlaxoSmithKline plc and Sanaria.
GlaxoSmithKline's RTS,S vaccine is the first and only malaria vaccine to receive regulatory approval. However, its efficacy of around 30% is below the WHO threshold. Sanaria's PfSPZ vaccine has shown higher protection of over 75% in phase 2 trials.
The growing burden of malaria and emergence of drug-resistant strains have increased the need for a highly effective vaccine. According to WHO, 229 million malaria cases were recorded globally in 2021 alone.
Leading developers are expanding vaccine production and conducting large-scale clinical trials in endemic regions to evaluate vaccine effectiveness in real-world settings. Partnerships with organizations supporting vaccine access in developing countries will be crucial for the global expansion of successful candidates.
Market Key Trends
One of the key trends in the Malaria Vaccines Market Size is the development of next-generation vaccine candidates with higher efficacy. While RTS,S provided a proof of concept, further research is focusing on improved antigen formulations and delivery methods to induce stronger and longer-lasting immune responses. nanoparticle entrapped vaccines and transmission-blocking approaches are some technologies being evaluated.
Sanaria's PfSPZ vaccine uses cryopreserved, aseptic, purified, non-replicating sporozoites to induce sterile protection. Phase 2 data found it 77% effective, making it a promising candidate. Other candidates in clinical trials include University of Oxford's ChAd63-MVA and Novavax’s R21.
Porter's Analysis
Threat of new entrants: High capital requirements and strict government regulations make entry difficult.
Bargaining power of buyers: Buyers have moderate bargaining power given limited product offerings and critical health needs.
Bargaining power of suppliers: Suppliers have moderate bargaining power as research requires specialized expertise and facilities.
Threat of new substitutes: No substitute for vaccine available currently making threat of substitution low.
Competitive rivalry: Intense as GlaxoSmithKline and Sanaria dominate the market with limited product differentiation.
Geographical regions
Currently, Africa accounts for majority of the market value due to high malaria burden in the region. Countries like Nigeria, Democratic Republic of Congo, Uganda account for bulk of global malaria cases driving high vaccine demand.
Asia Pacific region is expected to emerge as the fastest growing market between 2024-2031. Initiatives by governments and private organizations to reduce malaria prevalence through vaccination programs are supporting growth. Countries like India with large population and malaria cases represent significant opportunities. Rapid economic development and investment in healthcare infrastructure also favor regional expansion.
Get this Report in Japanese Language- マラリアワクチン市場
Get this Report in Korean Language- 말라리아 백신 시장
About Author-
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Known for her strong SEO background, she skillfully blends SEO strategies with insightful content. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment